Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association

Framework linking drug-specific mechanisms to endpoint selection and standardizing definitions of adverse CV events, including HF, arrhythmias, myocarditis and thrombotic events

Definitions of MACE, clinical events and surrogate endpoints, with alignment to the Common Terminology Criteria for Adverse Events and patient-reported outcomes

Practical guidance on prospective surveillance, decentralized and hybrid trial designs, independent endpoint adjudication, and statistical approaches to competing risks and late-emerging toxicities